Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $25.03M fell 5.7% year over year, behind the +75.7% change in trailing-twelve-month research & development. Sequentially, it fell 57.8% from the prior quarter. Over 3 fiscal years it compounded at +85.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -5.7% toward the trailing-twelve-month pace of +75.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 154.22M USD
- Year-over-year change
- +110.5%
- 4-year CAGR
- +41.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.22M | +110.5% |
| FY2024 | 2024-12-31 | 73.28M | +164.8% |
| FY2023 | 2023-12-31 | 27.67M | +14.1% |
| FY2022 | 2022-12-31 | 24.25M | -36.8% |
| FY2021 | 2021-12-31 | 38.4M | — |
Research & Development vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +75.7% is the highest of 11, against a peer median of -3.8%.
- Over three fiscal years its annual growth of +85.3% compares with a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $152.7M USD | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $126.01M USD | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $124.71M USD | +42.2% | +15.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M USD | +56.7% | +82.8% | — |
| LTM Mar 2026 | $66.77M USD | -12.8% | -2.0% | 185483.3% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M USD | -17.5% | +9.1% | — |
| LTM Mar 2026 | $58.79M USD | -15.8% | +15.8% | 1530.1% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| Peer median (excluding LRMR) | — | -3.8% | +15.7% | 1469.9% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.